Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening

#2898

Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.

Aim(s): We aim to overcome these challenges by establishing a method to culture SBNETs as spheroids for testing FDA-approved anti-cancer drugs and generating new patient-derived xenograft (PDX) models of SBNETs.

Materials and methods: Surgically resected SBNETs from patients were immediately processed, cultured as tumor spheroids, characterized for SBNET markers, and tested for sensitivity to 147 FDA-approved oncology drugs. In parallel, SBNET cells were injected into immunocompromised mice via intrasplenic injections to generate SBNET PDX models.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Kaemmer C, Ellen A,

Keywords: SBNET, drug screening, spheroids, PDX models, precision medicine,